Testing toripalimab plus chemo before salivary gland surgery
Part of Cancer, Ear, nose & throat clinical trials.
This trial studies toripalimab (an immune medicine) combined with chemotherapy given before surgery for salivary gland cancer. It aims to shrink the tumor and improve outcomes by using treatment early, before the operation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed salivary gland cancer and it’s planned to be treated with surgery to try to cure it.
- You are age 18 to under 80 when you enroll.
- You are well enough to do usual daily activities (ECOG 0 or 1).
- Your cancer has measurable signs on scans (measurable disease).
- You have not previously received immune checkpoint medicines like PD-1, PD-L1, PD-L2, or CTLA-4 antibodies.
- Recent blood tests show your liver, kidneys, bone marrow, and blood counts are in safe ranges.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving an immunotherapy drug (sintilimab) plus two chemotherapy medicines before surgery to shrink salivary gland cancer. The goal is to improve how well the cancer responds and is controlled, while still aiming for a cure through surgery.
This trial tests toripalimab (an immunotherapy) given before surgery for untreated head and neck squamous cell carcinoma, either alone or with chemotherapy. The goal is to shrink or control the cancer earlier and see if it improves outcomes for people who plan curative surgery.
This trial studies toripalimab to lower the risk of the cancer coming back after surgery and additional chemo-radiation. It may help the immune system “finish the job” after your main treatment, especially if you have higher-risk features.
This trial tests adding the immunotherapy drug toripalimab to chemotherapy after surgery for non-small cell lung cancer (NSCLC). It is for patients who either had no treatment before surgery or had chemo-immunotherapy before surgery and still have signs of cancer in their lymph nodes. The goal is to see if this combination helps prevent cancer from coming back.
This trial tests whether adding targeted radiation (SBRT) to a combination of chemotherapy and immunotherapy before surgery can improve outcomes for people with advanced mouth or throat cancer. It aims to shrink the tumor more effectively before removal.
This trial tests a combination of two drugs (MRG003 and Toripalimab) given before surgery to shrink head and neck cancer tumors. It's for people with a specific type of cancer that hasn't been treated before and is PD-L1 positive.
Hear when a new Salivary Gland Malignant Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.